Trial Profile
A Prospective Study of Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Mild-to-moderate Autoimmune Pulmonary Alveolar Proteinosis in China: a Randomized Open-label Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Therapeutic Use
- 29 Sep 2014 New trial record